Imjudo for Non-small cell lung cancer
Quick answer: Imjudo is used for Non-small cell lung cancer as part of a ctla-4 inhibitor (monoclonal antibody) treatment regimen. Tremelimumab is a human IgG2 monoclonal antibody that blocks CTLA-4, enhancing T-cell activation against tumors The specific dosing for Non-small cell lung cancer is determined by your prescriber based on individual factors.
Why is Imjudo used for Non-small cell lung cancer?
Imjudo belongs to the CTLA-4 inhibitor (monoclonal antibody) class. Tremelimumab is a human IgG2 monoclonal antibody that blocks CTLA-4, enhancing T-cell activation against tumors This action makes it useful for treating or managing Non-small cell lung cancer in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Imjudo is the right choice for a specific patient depends on the type and severity of Non-small cell lung cancer, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Non-small cell lung cancer
Common adult dosing range: 300 mg IV single priming dose with durvalumab, or 75 mg every 3 weeks. The actual dose for Non-small cell lung cancer depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Imjudo medicine page.
What to expect
Imjudo treatment for Non-small cell lung cancer typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Non-small cell lung cancer
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Imjudo is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all CTLA-4 inhibitor (monoclonal antibody) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Imjudo
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Imjudo full prescribing information · All CTLA-4 inhibitor (monoclonal antibody) alternatives
Frequently asked questions
How effective is Imjudo for Non-small cell lung cancer?
Effectiveness varies by individual response, dose, and severity. Imjudo is one of several treatment options for Non-small cell lung cancer, supported by clinical evidence within the ctla-4 inhibitor (monoclonal antibody) class. Discuss expected response with your prescriber.
How long do I need to take Imjudo for Non-small cell lung cancer?
Treatment duration depends on the nature of Non-small cell lung cancer — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Imjudo when used for Non-small cell lung cancer?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Imjudo for Non-small cell lung cancer?
Yes. Multiple medicines and non-drug options exist for Non-small cell lung cancer. Alternatives within the ctla-4 inhibitor (monoclonal antibody) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.